hero image

Eisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb)

March 7, 2024 Company Statements

Eisai will host its annual information meeting which will include information on LEQEMBI® (lecanemab-irmb).

Materials and an audio webcast will also be posted on the Eisai website following its investor event on Friday, March 8 at 1:30 pm JST/Thursday, March 7 at 11:30 pm ET.

thumb
April 24, 2024
BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report first quarter 2024 financial results Wednesday, April 24, 2024, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

thumb
March 31, 2024
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

TOKYO and CAMBRIDGE, Mass., April 1, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai submitted to the U.S.